NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $32,700.60 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 4,910 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $6.66, for a total transaction of $32,700.60. Following the transaction, the insider now owns 5,540,104 shares of the company’s stock, valued at approximately $36,897,092.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total transaction of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total transaction of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total transaction of $19,050.30.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total transaction of $23,126.46.

NeuroPace Stock Down 1.1 %

NPCE traded down $0.07 during midday trading on Friday, hitting $6.32. 5,487 shares of the company’s stock traded hands, compared to its average volume of 96,048. NeuroPace, Inc. has a one year low of $5.73 and a one year high of $18.15. The company has a market cap of $181.81 million, a PE ratio of -5.31 and a beta of 1.78. The company has a debt-to-equity ratio of 5.97, a current ratio of 6.37 and a quick ratio of 5.47. The stock’s fifty day simple moving average is $7.06 and its 200-day simple moving average is $8.46.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. NeuroPace had a negative net margin of 41.63% and a negative return on equity of 195.26%. The firm had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.30 million. During the same quarter in the previous year, the company earned ($0.36) earnings per share. The business’s revenue was up 16.6% compared to the same quarter last year. As a group, equities analysts anticipate that NeuroPace, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

A number of institutional investors have recently bought and sold shares of NPCE. Millennium Management LLC boosted its stake in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after purchasing an additional 80,324 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of NeuroPace by 18.3% in the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after purchasing an additional 75,512 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of NeuroPace in the 1st quarter valued at $621,000. Bank of New York Mellon Corp acquired a new stake in shares of NeuroPace in the 2nd quarter valued at $257,000. Finally, Rhumbline Advisers acquired a new stake in shares of NeuroPace in the 2nd quarter valued at $111,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Wells Fargo & Company reduced their price target on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Morgan Stanley reduced their price target on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, NeuroPace has an average rating of “Moderate Buy” and a consensus price target of $14.00.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.